Embedded and impacted teeth.
Conditions
Interventions
In the test group, 40 volunteers will receive 2 oral tablets of Remilev® (totaling 500 mg of Valeriana officinalis L. and 120 mg of Humulus lupulus L. (extract ZE91019, Aché Laboratórios Farmacêuticos
Drug
Procedure/surgery
C07.793.846
Sponsors
Universidade Federal de Sergipe
Universidade Federal de Sergipe
Eligibility
Age
No minimum to 30 Months
Inclusion criteria
Inclusion criteria: Healthy volunteers ASA I; age between 18 and 30 years; presence of bilateral mandibular third molars included, asymptomatic and in similar positions and surgical difficulties based on the internationally accepted scientific classification of Pell and Gregory, verified by current panoramic radiography.
Exclusion criteria
Exclusion criteria: Patients ASAIII or IV; history of use of any type of anxiolytic drug in the 15 days prior to the beginning of the research; history of hypersensitivity to drugs, substances or materials used in this experiment; pregnancy or lactation; previous history of pericoronaritis; extremely anxious or odontophobic patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean difference of at least 20 mmHg of systolic blood pressure, measured during the intraoperative period with digital pulse monitor, between the two treatments (test and control). | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of the degree of anxiety of the patients through questionnaires (CORAH).;Number of collateral effects after the use of the medication. | — |
Countries
Brazil
Contacts
Public ContactAntonio Silva dos Santos
Universidade Federal de Sergipe
Outcome results
None listed